The Next Frontier: The Oral Small Molecule GLP-1s While injectable peptides like semaglutide and tirzepatide have revolutionized treatment, they are not the endgame
Nine trials were conducted in participants with overweight and/or obesity (Reference Ahmed Al-Naggar, Osman and Abdulghani23,Reference Alperet, Rebello and Khoo24,Reference Basu, Betts and Mulugeta26,Reference Cardoso, Salgado and Cesar28,Reference Kobayashi, Kawano and Ukawa31,Reference Mousavi, Vafa and Neyestani35,Reference Nabi, Sedighinejad and Haghighi37,Reference Ohnaka, Ikeda and Maki38,Reference Wedick, Brennan and Sun44) and nine in healthy participants (Reference Ahmed Al-Naggar, Osman and Abdulghani23,Reference Hochkogler, Schweiger and Rust29Reference Lecoultre, Carrel and Egli32,Reference Revuelta-Iniesta and Al-Dujaili39,Reference Superko, Bortz and Williams40,Reference van Dusseldorp, Katan and van Vliet42,Reference Wedick, Brennan and Sun44)
This is largely due to the high concentration of glycine found in collagen
Mild to moderate stomach pain, bloating, and nausea are expected side effects of GLP-1 therapy and are not dangerous in themselves